Latest Stories
3 Reasons to Sell DGX and 1 Stock to Buy Instead
Quest trades at $179.96 and has moved in lockstep with the market. Its shares have returned 6.9% over the last six months while the S&P 500 has gained 11.3%.
3 Reasons to Sell ALSN and 1 Stock to Buy Instead
Since January 2021, the S&P 500 has delivered a total return of 83.7%. But one standout stock has nearly doubled the market - over the past five years, Allison Transmission has surged 156% to $105.96 per share. Its momentum hasn’t stopped as it’s also gained 16.8% in the last six months, beating the S&P by 5.6%.
3 Big Reasons to Love Warby Parker (WRBY)
Warby Parker’s 26.4% return over the past six months has outpaced the S&P 500 by 15.1%, and its stock price has climbed to $29.08 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
3 Reasons SOLV is Risky and 1 Stock to Buy Instead
Solventum trades at $79.45 per share and has stayed right on track with the overall market, gaining 7.3% over the last six months. At the same time, the S&P 500 has returned 11.3%.
3 Reasons KMX is Risky and 1 Stock to Buy Instead
CarMax has gotten torched over the last six months - since July 2025, its stock price has dropped 29.3% to $46.12 per share. This might have investors contemplating their next move.
3 Reasons to Avoid MED and 1 Stock to Buy Instead
Over the past six months, Medifast’s stock price fell to $11.62. Shareholders have lost 18.9% of their capital, which is disappointing considering the S&P 500 has climbed by 11.3%. This might have investors contemplating their next move.
3 Reasons to Avoid FIBK and 1 Stock to Buy Instead
First Interstate BancSystem’s 16.5% return over the past six months has outpaced the S&P 500 by 5.3%, and its stock price has climbed to $36.48 per share. This performance may have investors wondering how to approach the situation.
ResMed (RMD): Buy, Sell, or Hold Post Q3 Earnings?
Since July 2025, ResMed has been in a holding pattern, floating around $254.41. The stock also fell short of the S&P 500’s 11.3% gain during that period.
3 Reasons OCUL is Risky and 1 Stock to Buy Instead
Over the last six months, Ocular Therapeutix’s shares have sunk to $10.44, producing a disappointing 7.4% loss - a stark contrast to the S&P 500’s 11.3% gain. This might have investors contemplating their next move.
Impinj (PI): Buy, Sell, or Hold Post Q3 Earnings?
Impinj has been on fire lately. In the past six months alone, the company’s stock price has rocketed 72.2%, reaching $194.03 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.